ChromaDex Stock Forecast, Price & News

ChromaDex's stock was trading at $3.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDXC shares have increased by 25.8% and is now trading at $4.63.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ChromaDex.

ChromaDex is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for ChromaDex.

ChromaDex will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

ChromaDex Co. (NASDAQ:CDXC) posted its earnings results on Thursday, August, 6th. The company reported ($0.06) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.05. The business earned $15.29 million during the quarter, compared to the consensus estimate of $13.56 million. ChromaDex had a negative net margin of 46.86% and a negative return on equity of 103.66%.
View ChromaDex's earnings history.

3 brokerages have issued 12 month target prices for ChromaDex's stock. Their forecasts range from $7.00 to $9.00. On average, they anticipate ChromaDex's stock price to reach $7.67 in the next year. This suggests a possible upside of 65.6% from the stock's current price.
View analysts' price targets for ChromaDex.

ChromaDex saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 2,590,000 shares, an increase of 12.1% from the September 30th total of 2,310,000 shares. Based on an average daily trading volume, of 344,200 shares, the short-interest ratio is currently 7.5 days. Currently, 6.8% of the company's shares are short sold.
View ChromaDex's Short Interest.

Some companies that are related to ChromaDex include Tilray (TLRY), Aurora Cannabis (ACB), Canopy Rivers (RIV), Mediwound (MDWD), Charlie's (CHUC), Natural Alternatives International (NAII), Happiness Biotech Group (HAPP), Mannatech (MTEX), FSD Pharma (HUGE), Glucose Health (GLUC), Sundial Growers (SNDL), Cyanotech (CYAN), FitLife Brands (FTLF), True Drinks (TRUU) and GLG Life Tech (GLGLF).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ChromaDex investors own include Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), ADMA Biologics (ADMA), Athersys (ATHX), BioNano Genomics (BNGO), Matinas BioPharma (MTNB), Tilray (TLRY), Dynavax Technologies (DVAX), Glu Mobile (GLUU) and Great Panther Mining (GPL).

ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."

ChromaDex's stock is owned by a number of institutional and retail investors. Top institutional investors include Cambridge Investment Research Advisors Inc. (0.06%), Nisa Investment Advisors LLC (0.02%) and Campbell & CO Investment Adviser LLC (0.02%). Company insiders that own ChromaDex stock include Kevin M Farr, Robert N Fried and Stephen A Block.
View institutional ownership trends for ChromaDex.

CDXC stock was purchased by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc., Nisa Investment Advisors LLC, and Campbell & CO Investment Adviser LLC. Company insiders that have bought ChromaDex stock in the last two years include Kevin M Farr, and Robert N Fried.
View insider buying and selling activity for ChromaDex.

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDXC stock can currently be purchased for approximately $4.63.

ChromaDex has a market capitalization of $285.32 million and generates $46.29 million in revenue each year. The company earns $-32,150,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. ChromaDex employs 110 workers across the globe.

The official website for ChromaDex is www.chromadex.com.

ChromaDex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected]